Zymeworks Inc. (ZYME) |
|
8.38 -0.54 (-6.05%)
|
03-22 16:00 |
|
Open: |
8.92 |
Pre. Close: |
8.92 |
|
High:
|
8.92 |
Low:
|
8.36 |
|
Volume:
|
420,681 |
Market Cap:
|
537(M) |
|
|
|
Technical analysis |
as of: 2023-03-22 3:52:46 PM |
|
Overall:
|
  |
| Stoxline posted a NEUTRAL today, downgraded from higher rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
| Target: |
Six months: 10.62 One year: 12.41 |
| Support: |
Support1: 8.06 Support2: 7.42 |
| Resistance: |
Resistance1: 9.1 Resistance2: 10.62 |
| Pivot: |
8.25  |
| Moving Average: |
MA(5): 8.51 MA(20): 8.28
MA(100): 8.19 MA(250): 6.89 |
| MACD: |
MACD(12,26): -0.1 Signal(9): -0.2 |
| Stochastic oscillator: |
%K(14,3): 80.4 %D(3): 75 |
| RSI: |
RSI(14): 49.8 |
| 52-week: |
High: 10.8 Low: 4.11 |
| Average Vol(K): |
3-Month: 737 (K) 10-Days: 591 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ ZYME ] has closed below upper band by 32.4%. Bollinger Bands are 43.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 10 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
8.95 - 8.99 |
8.99 - 9.02 |
|
Low:
|
8.39 - 8.43 |
8.43 - 8.47 |
|
Close:
|
8.85 - 8.92 |
8.92 - 8.98 |
|
Company Description |
|
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, breast, and colorectal cancer; and ZW49, a biparatopic anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; BeiGene, Ltd.; and Exelixis, Inc. It also has licensing and research collaboration with LEO Pharma A/S to research, develop, and commercialize bispecific antibodies; and Iconic Therapeutics, Inc. Zymeworks Inc. was incorporated in 2003 and is headquartered in Vancouver, Canada. |
Headline News |
Tue, 21 Mar 2023
Zymeworks (NYSE:ZYME) Receives "Overweight" Rating from Wells ... - MarketBeat
Mon, 20 Mar 2023
Daiichi, Zymeworks Terminate Seven Year-Cancer Antibody Pact - Yahoo Finance
Wed, 15 Mar 2023
Zymeworks Inc. (ZYME) Gains As Market Dips: What You Should Know - Zacks Investment Research
Tue, 14 Mar 2023
Zymeworks to Present Updated Data on Multiple Product ... - Business Wire
Mon, 13 Mar 2023
Analysts Forecast Zymeworks Inc.'s Earnings in the First Quarter of ... - Best Stocks
Thu, 09 Mar 2023
Zymeworks Offers Hope for More than Just Long-Term Investors - Nasdaq
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Neutral |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Outperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Outperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NYSE |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
0 (M) |
| Shares Float |
64 (M) |
|
% Held by Insiders
|
3.441e+007 (%) |
|
% Held by Institutions
|
4.9 (%) |
|
Shares Short
|
7,340 (K) |
|
Shares Short P.Month
|
0 (K) |
Stock Financials |
|
EPS
|
1.3505e+008 |
|
EPS Est Next Qtl
|
-0.68 |
|
EPS Est This Year
|
-2.99 |
|
EPS Est Next Year
|
-2.54 |
|
Book Value (p.s.)
|
0 |
|
Profit Margin (%)
|
30.1 |
|
Operating Margin (%)
|
31.2 |
|
Return on Assets (ttm)
|
15.5 |
|
Return on Equity (ttm)
|
33.5 |
|
Qtrly Rev. Growth
|
1 |
|
Gross Profit (p.s.)
|
1017.14 |
|
Sales Per Share
|
4.53275e+008 |
|
EBITDA (p.s.)
|
2.23934e+008 |
|
Qtrly Earnings Growth
|
-4 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
144 (M) |
Stock Valuations |
|
PE Ratio
|
0 |
|
PEG Ratio
|
-0.5 |
|
Price to Book value
|
0 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
0.98 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
7.07e+006 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
